Welcome to our dedicated page for Ascendis Pharma news (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma stock.
Ascendis Pharma A/S (NASDAQ: ASND) is a global biopharmaceutical company that develops therapies using its proprietary TransCon technology platform. This news page aggregates company announcements, clinical updates, financial results, and regulatory milestones that Ascendis discloses through press releases and regulatory channels.
Readers can follow developments related to Ascendis’ commercial products and pipeline, including YORVIPATH (TransCon PTH) for adults with hypoparathyroidism and SKYTROFA (TransCon hGH) for pediatric and adult growth hormone deficiency. News items also cover investigational programs such as TransCon CNP for children with achondroplasia, combination therapy with TransCon CNP and TransCon hGH in the COACH trial, and TransCon IL-2 β/γ in late-line platinum-resistant ovarian cancer.
Updates frequently include information on Phase 2 and Phase 3 clinical trial results, publication of pivotal data in peer-reviewed journals, submissions and reviews of New Drug Applications and Marketing Authorisation Applications, and presentations at major medical and investor conferences. Financial news, such as quarterly results, revenue contributions from YORVIPATH and SKYTROFA, and commentary on the company’s progress toward its long-term vision, is also reported.
Investors and observers can use this page to monitor how Ascendis advances its TransCon-based portfolio across endocrinology, rare diseases, and oncology, as well as to track collaboration news involving partners in regions such as Greater China and Japan. For those following ASND stock, the news flow provides context on the company’s operational performance, regulatory interactions, and clinical milestones over time.
Ascendis Pharma (Nasdaq: ASND) announced a board transition with Michael Wolf Jensen stepping down as Chair at the 2021 AGM but remaining as SVP and Chief Legal Officer. The Board intends to appoint Dr. Albert Cha as the new Chair. Jensen has been with the company since 2008, guiding its transformation into a global organization. Dr. Cha has been on the Board since 2014 and has experience in healthcare investment. Ascendis continues to innovate with its TransCon technologies, focusing on rare diseases and expanding into oncology.
Ascendis Pharma A/S (Nasdaq: ASND) announced its participation in the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 3, 2020. Executives will provide an update on the company's pipeline and business overview. The event will be streamed live, with a replay available for 30 days on the company’s website. Ascendis is focused on developing innovative therapies using its TransCon technologies, currently advancing clinical programs in endocrinology and oncology, while expanding into additional therapeutic areas to address unmet patient needs.
Ascendis Pharma A/S (Nasdaq: ASND) announced its upcoming virtual Oncology R&D Day on November 20, 2020, at 12:00 p.m. ET. The event will showcase the application of its innovative TransCon™ technology platform to oncology, highlighting the company’s strategy and developments in creating new cancer therapies. Key focuses include updates on TransCon TLR7/8 Agonist and TransCon IL-2 β/γ programs, which aim to activate immune responses in cancer treatment. A live webcast will be available on the company’s website, with a replay accessible for 30 days post-event.
Ascendis Pharma announced the validation of its Marketing Authorisation Application (MAA) for TransCon hGH (lonapegsomatropin) in pediatric growth hormone deficiency by the European Medicines Agency (EMA). The company has also submitted regulatory filings for the phase 3 PaTHway Trial of TransCon PTH in Europe and Canada, and initiated a phase 2 trial for TransCon CNP in collaboration with VISEN Pharmaceuticals. Ascendis reported a net loss of €121.7 million for Q3 2020, with revenues increasing to €2.8 million. Cash reserves stand at €957.5 million as of September 30, 2020.
Ascendis Pharma A/S (Nasdaq: ASND) has appointed Mark A. Bach, M.D., Ph.D., as Senior Vice President of Clinical Development and Medical Affairs focusing on endocrine rare diseases. His extensive experience in clinical research and development is expected to bolster the company's investigational product pipeline, particularly as it prepares for the potential launch of its first product targeting pediatric growth hormone deficiency. The company utilizes its proprietary TransCon technology to develop innovative therapies aimed at unmet medical needs in endocrinology.
Ascendis Pharma A/S (Nasdaq: ASND) will hold a conference call on November 11, 2020, at 4:30 p.m. ET to discuss its Q3 2020 financial results and provide a business update. Interested parties can dial in using 844-290-3904 (U.S.) or 574-990-1036 (international) with access code 8955314. The call will be available via webcast on their website, with a replay accessible for 30 days thereafter. Ascendis aims to leverage its innovative TransCon technologies to advance in endocrinology and oncology.
Ascendis Pharma A/S (Nasdaq: ASND) announced that the European Commission has granted Orphan Designation to its investigational drug, TransCon PTH, for treating hypoparathyroidism. This long-acting prodrug aims to normalize parathyroid hormone levels, addressing both short-term and long-term symptoms of the condition. Currently, patients are treated with calcium and vitamin D supplements, which are insufficient. The Orphan Designation enhances market exclusivity and reimbursement prospects for the drug, which has also received similar recognition from the U.S. FDA.
Ascendis Pharma A/S (Nasdaq: ASND) announced five presentations highlighting its endocrinology rare disease programs at two online medical conferences: ECTS 2020 (October 22-24) and PENS (November 2-5). Key data includes phase 2 results of TransCon PTH for hypoparathyroidism and phase 3 fliGHt Trial outcomes for TransCon hGH in pediatric growth hormone deficiency. The company aims to enhance clinical outcomes and quality of life for patients. The presentations will showcase a novel auto-injector and research on achondroplasia's impact on children.
Ascendis Pharma A/S (Nasdaq: ASND) has filed a Clinical Trial Notification with Japan's PMDA to initiate the phase 3 riGHt Trial for TransCon™ hGH, targeting pediatric growth hormone deficiency (GHD). This trial is significant as it aims to compare the height velocity of treated Japanese children against a daily hGH formulation, enhancing the product's global reach. The trial involves 40 treatment-naïve children and is expected to support marketing applications in Japan, crucial for expanding Ascendis' product offerings.
Ascendis Pharma A/S (Nasdaq: ASND) has launched the #Together4Growth campaign to raise awareness about children's growth disorders during Children’s Growth Awareness Week, from September 13-19, 2020. This initiative includes a four-question Growth Quiz for parents to identify symptoms and encourages discussion with healthcare professionals. The campaign emphasizes the importance of monitoring growth patterns and will culminate in International Children’s Growth Awareness Day on September 20, 2020. Ascendis Pharma aims to improve life quality for affected children through education and resources.